Now, the U.S. Food and Drug Administration (FDA) has approved a pill form of Wegovy. This shockingly effective weight-loss medication was originally developed by the Danish pharmaceutical company Novo Nordisk to treat diabetes. This approval signals a new era in combating obesity with a significantly expanded range of treatment options. In addition, Wegovy is now the only GLP-1 (glucagon-like peptide-1) drug available orally.
Wegovy — previously only available as an injection — has become well-known for its power to help people lose significant amounts of weight. The FDA’s approval specifically targets individuals seeking to manage their weight, providing them with a convenient alternative to the injectable version. Patients would find it easier to take a newly approved once-a-day pill, to bring it more easily into their daily routines, the FDA said.
Today, Novo Nordisk shared some pretty exciting news! Now, the pill version of Wegovy has demonstrated providing the same weight loss benefits as its injectable counterpart. It is this consistency that provides patients with the same predictable outcome, regardless of how it is delivered. The company’s commitment to bringing forth innovative solutions as a means to address obesity is well represented in the development of this new oral formulation.
Novo Nordisk’s move to introduce a pill form of Wegovy reflects a growing demand for more accessible and user-friendly medication options. Next, injectables are often cumbersome for patients. The once-daily pill provides a simple, convenient option that can improve adherence to treatment.
A landmark approval of this oral medication has arrived after years of growing alarm over the United States’ skyrocketing obesity rates. The FDA’s approval sends a strong signal about the need to provide science-backed, effective treatment options to people who are challenged by their weight. With Wegovy now available in both injectable and pill forms, patients have more flexibility in choosing a treatment that best suits their lifestyle.